- Home
- CWK vs APGE Comparison
CWK vs APGE Comparison
Compare CWK & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- APGE
- Stock Information
- Founded
- CWK 1784
- APGE 2022
- Country
- CWK United States
- APGE United States
- Employees
- CWK N/A
- APGE N/A
- Industry
- CWK Real Estate
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CWK Finance
- APGE Health Care
- Exchange
- CWK Nasdaq
- APGE Nasdaq
- Market Cap
- CWK 2.7B
- APGE 2.6B
- IPO Year
- CWK 2018
- APGE 2023
- Fundamental
- Price
- CWK $11.71
- APGE $38.14
- Analyst Decision
- CWK Hold
- APGE Strong Buy
- Analyst Count
- CWK 7
- APGE 4
- Target Price
- CWK $13.43
- APGE $97.50
- AVG Volume (30 Days)
- CWK 2.0M
- APGE 1.3M
- Earning Date
- CWK 07-28-2025
- APGE 08-11-2025
- Dividend Yield
- CWK N/A
- APGE N/A
- EPS Growth
- CWK 1337.16
- APGE N/A
- EPS
- CWK 0.69
- APGE N/A
- Revenue
- CWK $9,546,300,000.00
- APGE N/A
- Revenue This Year
- CWK $5.77
- APGE N/A
- Revenue Next Year
- CWK $5.65
- APGE $743.14
- P/E Ratio
- CWK $17.00
- APGE N/A
- Revenue Growth
- CWK 1.24
- APGE N/A
- 52 Week Low
- CWK $7.64
- APGE $26.20
- 52 Week High
- CWK $16.11
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- CWK 63.15
- APGE 43.45
- Support Level
- CWK $11.26
- APGE $36.40
- Resistance Level
- CWK $11.90
- APGE $39.33
- Average True Range (ATR)
- CWK 0.37
- APGE 3.04
- MACD
- CWK 0.04
- APGE -0.83
- Stochastic Oscillator
- CWK 87.25
- APGE 20.25
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.